These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20231677)

  • 1. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
    Doi T; Muro K; Boku N; Yamada Y; Nishina T; Takiuchi H; Komatsu Y; Hamamoto Y; Ohno N; Fujita Y; Robson M; Ohtsu A
    J Clin Oncol; 2010 Apr; 28(11):1904-10. PubMed ID: 20231677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
    Ohtsu A; Ajani JA; Bai YX; Bang YJ; Chung HC; Pan HM; Sahmoud T; Shen L; Yeh KH; Chin K; Muro K; Kim YH; Ferry D; Tebbutt NC; Al-Batran SE; Smith H; Costantini C; Rizvi S; Lebwohl D; Van Cutsem E
    J Clin Oncol; 2013 Nov; 31(31):3935-43. PubMed ID: 24043745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
    Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC
    Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
    Yoon DH; Ryu MH; Park YS; Lee HJ; Lee C; Ryoo BY; Lee JL; Chang HM; Kim TW; Kang YK
    Br J Cancer; 2012 Mar; 106(6):1039-44. PubMed ID: 22343617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
    Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
    Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
    Wainberg ZA; Soares HP; Patel R; DiCarlo B; Park DJ; Liem A; Wang HJ; Yonemoto L; Martinez D; Laux I; Brennan M; Hecht JR
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):61-7. PubMed ID: 25969130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
    Ray-Coquard I; Favier L; Weber B; Roemer-Becuwe C; Bougnoux P; Fabbro M; Floquet A; Joly F; Plantade A; Paraiso D; Pujade-Lauraine E
    Br J Cancer; 2013 May; 108(9):1771-7. PubMed ID: 23612453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
    Soria JC; Shepherd FA; Douillard JY; Wolf J; Giaccone G; Crino L; Cappuzzo F; Sharma S; Gross SH; Dimitrijevic S; Di Scala L; Gardner H; Nogova L; Papadimitrakopoulou V
    Ann Oncol; 2009 Oct; 20(10):1674-81. PubMed ID: 19549709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
    Besse B; Leighl N; Bennouna J; Papadimitrakopoulou VA; Blais N; Traynor AM; Soria JC; Gogov S; Miller N; Jehl V; Johnson BE
    Ann Oncol; 2014 Feb; 25(2):409-15. PubMed ID: 24368400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
    Ghobrial IM; Gertz M; Laplant B; Camoriano J; Hayman S; Lacy M; Chuma S; Harris B; Leduc R; Rourke M; Ansell SM; Deangelo D; Dispenzieri A; Bergsagel L; Reeder C; Anderson KC; Richardson PG; Treon SP; Witzig TE
    J Clin Oncol; 2010 Mar; 28(8):1408-14. PubMed ID: 20142598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of everolimus in metastatic urothelial cancer.
    Milowsky MI; Iyer G; Regazzi AM; Al-Ahmadie H; Gerst SR; Ostrovnaya I; Gellert LL; Kaplan R; Garcia-Grossman IR; Pendse D; Balar AV; Flaherty AM; Trout A; Solit DB; Bajorin DF
    BJU Int; 2013 Aug; 112(4):462-70. PubMed ID: 23551593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
    Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
    Zhu AX; Abrams TA; Miksad R; Blaszkowsky LS; Meyerhardt JA; Zheng H; Muzikansky A; Clark JW; Kwak EL; Schrag D; Jors KR; Fuchs CS; Iafrate AJ; Borger DR; Ryan DP
    Cancer; 2011 Nov; 117(22):5094-102. PubMed ID: 21538343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.